Adverse effects of long-term proton pump inhibitor use: A review for the otolaryngologist

Journal of Voice

Volumn 25, Issue 2, 2011, Pages 236-240

  Chapman, D Brandon ^a   Rees, Catherine J ^a   Lippert, Dylan ^a   Sataloff, Robert T ^b   Wright Jr , S Carter ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antacid; Complications of proton pump inhibitor; Laryngopharyngeal reflux; Proton pump inhibitor; Reflux

Indexed keywords

CLOPIDOGREL; CYANOCOBALAMIN; GASTRIN; IRON; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ATROPHIC GASTRITIS; BACTERIUM EXAMINATION; BONE DENSITY; CALCIUM ABSORPTION; CARDIOLOGIST; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIZZINESS; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; GASTRIN BLOOD LEVEL; HEADACHE; HEALTH CARE PERSONNEL; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; LARYNGOPHARYNGEAL REFLUX; LONG TERM EXPOSURE; MEDLINE; NAUSEA AND VOMITING; NONHUMAN; OTORHINOLARYNGOLOGY; STOMACH CARCINOMA;

DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; OTOLARYNGOLOGY; PROTON PUMP INHIBITORS; REGURGITATION, GASTRIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79951943943     PISSN: 08921997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvoice.2009.10.015     Document Type: Article

References (32)

1. J.A. Koufman, J.E. Aviv, R.R. Casiano, and G.Y. Shaw Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery Otolaryngol Head Neck Surg 127 2002 32 35 (Pubitemid 41115024)
2. J.A. Koufman, G.J. Wiener, C.W. Wallace, and D.O. Castell Reflux laryngitis and its sequelae: the diagnostic role of ambulatory 24-hour pH monitoring J Voice 2 1988 78 89
3. J.A. Koufman Laryngopharyngeal reflux is different from classic gastroesophageal reflux disease Ear Nose Throat J 81 Suppl 2 2002 7 9
4. J.W. Mims The impact of extra-esophageal reflux upon disease of the upper respiratory tract Curr Opin Otolaryngol Head Neck Surg 16 2008 242 246 (Pubitemid 351677659)
5. J.A. Koufman The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury Laryngoscope 101 Suppl 53 1991 1 78
6. G.N. Postma, L.F. Johnson, and J.A. Koufman Treatment of laryngopharyngeal reflux Ear Nose Throat J 81 Suppl 2 2002 24 26
7. L. Eslami, S. Kalantarian, and S. Nasseri-Moghaddam Long term proton pump inhibitor use and the incidence of gastric (pre) malignant lesions Cochrane Database Syst Rev. 2 2008 CD007098
8. V. Savarino, F. Di Mario, and C. Scarpignato Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety Pharmacol Res 59 2009 135 153
9. M. Davies, L.V. Wilton, and S.A.W. Shakir Safety profile of esomeprazole: results of a prescription-event monitoring study of 11595 patients in England Drug Saf 31 4 2008 313 323 (Pubitemid 351441579)
10. C.J. Carr, and R.F. Shangraw Nutritional and pharmaceutical aspects of calcium supplementation Am Pharm NS27 1987 49 57 (Pubitemid 18076383)
11. M.B. O'Connell, D.M. Madden, A.M. Murray, R.P. Heaney, and L.J. Kerzner Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial Am J Med 118 2005 778 781 (Pubitemid 40897665)
12. G. Granziani, G. Como, and S. Badalamenti Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects Nephrol Dial Transplant 10 1995 1376 1380
13. E.L. Hannan, J. Magaziner, and J.J. Wang Mortality and locomotion 6 months after hospitalization for hip fracture: risk factors and risk-adjusted hospital outcomes JAMA 285 2001 2736 2742 (Pubitemid 32525370)
14. Y.X. Yang, J.D. Lewis, S. Epstein, and D.C. Metz Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2006 2947 2953 (Pubitemid 46021498)
15. L.E. Targownik, L.M. Lix, C.J. Metge, H.J. Prior, S. Leung, and W.D. Leslie Use of proton pump inhibitors and risk of osteoporosis-related fractures CMAJ 179 2008 319 326
16. R.J. Valuck, and J.M. Ruscin A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults J Clin Epidemiol 57 2004 422 428 (Pubitemid 38609284)
17. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 2009 148e1-148e5
18. M. Aseeri, T. Schroeder, J. Kramer, and R. Zackula Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients Am J Gastroenterol 103 2008 2308 2313
19. M. Sarkar, S. Hennessy, and Y.X. Yang Proton-pump inhibitor use and the risk for community-acquired pneumonia Ann Intern Med 149 2008 391 398
20. S.E. Gulmez, A. Holm, H. Frederiksen, T.G. Jensen, C. Pedersen, and J. Hallas Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study Arch Intern Med 167 2007 950 955 (Pubitemid 46762758)
21. R.J. Laheij, M.C. Sturkenboom, R.J. Hassing, J. Dieleman, B.H. Stricker, and J.B. Jansen Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs JAMA 292 2004 1955 1960 (Pubitemid 39411203)
22. S.J. Herzig, M.D. Howell, L.H. Ngo, and E.R. Marcantonio Acid-suppressive medication use and the risk for hospital-acquired pneumonia JAMA 301 2009 2120 2128
23. M. Gilard, B. Arnaud, and J.C. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
24. E. Pezalla, D. Day, and I. Pulliadath Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors J Am Coll Cardiol 52 2008 1038 1039
25. P.M. Ho, T.M. Maddox, L. Wang, S.D. Fihn, R.L. Jesse, E.D. Peterson, and J.S. Rumsfeld Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
26. D.N. Juurlink, T. Gomes, and D.T. Ko A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
27. T.B. Nealis, and C.W. Howden Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther 15 2008 536 542
28. M. Jalving, J.J. Koornstra, J. Wesseling, H.M. Boezen, S.D.E. Jong, and J.H. Kleibeuker Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy Aliment Pharmacol Ther 24 2006 1341 1348 (Pubitemid 44571564)
29. J.W. Freston Omeprazole, hypergastrinemia, and gastric carcinoid tumors Ann Intern Med 121 1994 232 233 (Pubitemid 24225641)
30. FDA Omeprazole Drug Information. Food and Drug Administration website Available at: www.fda.gov/cder/foi/label/2006/019810s083lbl.pdf Accessed May 16, 2009
31. H. Tamim, A. Duranceau, L.Q. Chen, and J. Lelorier Association between use of acid-suppressive drugs and risk of gastric cancer: a nested case-control study Drug Saf 31 2008 675 684 (Pubitemid 352019565)
32. A.H. Poulsen, S. Christensen, J.K. McLaughlin, R.W. Thomsen, H.T. Sorensen, J.H. Olsen, and S. Friis Proton pump inhibitors and risk of gastric cancer: a population-based cohort study Br J Cancer 100 2009 1503 1507